Myriad Genetics (MYGN) director sells 15,000 shares under 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Myriad Genetics Inc. director Rashmi Kumar sold 15,000 shares of Common Stock in an open-market transaction. The shares were sold on 2026-06-08 at a weighted average price of $4.4562 per share, in multiple trades ranging from $4.37 to $4.63.
After this sale, Kumar directly owns 171,889 shares of Myriad Genetics Common Stock. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 15,000 shares ($66,843)
Net Sell
1 txn
Insider
Kumar Rashmi
Role
null
Sold
15,000 shs ($67K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 15,000 | $4.4562 | $67K |
Holdings After Transaction:
Common Stock — 171,889 shares (Direct, null)
Footnotes (1)
- The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.37 to $4.63, inclusive. The reporting person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Key Figures
Shares sold: 15,000 shares
Average sale price: $4.4562 per share
Post-transaction holdings: 171,889 shares
+2 more
5 metrics
Shares sold
15,000 shares
Open-market sale on 2026-06-08
Average sale price
$4.4562 per share
Weighted average price for 15,000 shares
Post-transaction holdings
171,889 shares
Shares directly owned after sale
Low sale price in range
$4.37 per share
Lowest individual trade price in sale range
High sale price in range
$4.63 per share
Highest individual trade price in sale range
Key Terms
Rule 10b5-1 trading plan, weighted average price, open-market sale, Common Stock, +1 more
5 terms
Rule 10b5-1 trading plan financial
"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action: "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Common Stock financial
"security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Form 4 regulatory
"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
What insider transaction did Myriad Genetics (MYGN) disclose for Rashmi Kumar?
Myriad Genetics reported that director Rashmi Kumar sold 15,000 shares of Common Stock. The open-market sale occurred at a weighted average price of $4.4562 per share, executed in multiple trades within a disclosed price range.
Was the Myriad Genetics (MYGN) insider sale made under a Rule 10b5-1 plan?
Yes. The Form 4 states that the transactions were effected pursuant to a Rule 10b5-1 trading plan. Such pre-arranged plans allow insiders to systematically sell shares according to predetermined instructions, independent of subsequent market developments.
What type of transaction was reported for Myriad Genetics (MYGN) director Rashmi Kumar?
The filing describes the transaction as an open-market sale of Common Stock. It is coded as a “S” transaction, indicating a sale in the open market or a private transaction, rather than an option exercise, gift, or tax-withholding event.